| Name | Title | Contact Details |
|---|
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost. For further information on how we are transforming the administration of parenteral drugs.
Barry`s game-changing fitness classes offer our global community, the OG #FitFam, the Best Workout in the World® -- a workout that is as effective as it is fun. Founded in 1998, Barry`s has led the fitness industry in innovation. Today, you can experience our signature Red Room in more than 70 studios across 10 countries, as well as in the comfort of your own home. Whether you`re sprinting, lifting, or riding, in-studio or at-home, we`re on a mission to inspire you to work(out) hard, have fun, find your strength, and be your best.
Intergrated Medical Professionals is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orion Medical Management is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.